Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

6. Danaher Corp. ( DHR) is a science and technology company.

In August, Danaher completed the acquisition of Beckman Coulter, which makes products used in biomedical testing.

The deal was a cash tender offer for all of Beckman Coulter's outstanding shares of common stock at a purchase price of $83.50 per share for a total consideration of $6.9 billion, including debt assumed and net of cash acquired.

Of the 24 analysts covering Danaher, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 17.4% to $55.95 in the coming 12 months.

If you liked this article you might like

Here's How to Invest Like a Billionaire

The Dow Binges on Earnings

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens